



Contra Costa Health Plan
P&T Formulary Update
July 7, 2017

Volume 2

Changes effective: 8/1/2017

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On July 7, 2017 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
- Alzheimer's Disease - Genital Warts - Human Immunodeficiency Virus - PCSK9 Inhibitors - Needles & Pen Needles - Diuretics - Topical Pain Medications - Progestins	- Gaucher's Disease - GLP-1 Agonists - Local Anesthetics - Neuropathic Pain and Fibromyalgia - Pancreatic Enzymes - Systemic Contraceptives - Statins - Topical estrogens
Drug Monographs	
- Xiidra (lifitegrast) ophthalmic solution - Lialda (mesalamine)	
Prior Authorization Criteria	
- Xiidra (lifitegrast) ophthalmic solution - Trutrack, Truetest (diabetes test strips) – criteria for use for T1DM during pregnancy - GLP-1 Agonist: Victoza (liraglutide) - Tanzeum (albiglutide) - PCSK9 inhibitors (draft criteria presented, not approved)	
Guest Speaker(s)	
None	

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Victoza (liraglutide)	Add to formulary with metformin step therapy. Quantity limit 3 x 3mL pens/month.
Tanzeum (albiglutide)	Add to formulary with metformin step therapy. Quantity limit #4 pens/month.
Xiidra (lifitegrast) 5% Ophthalmic	Add PA criteria: must try and fail artificial tears drops and ointment (same criteria as Restasis). Applies to all members.
Diabetes test strips (TrueTrack, TrueMetrix)	PA criteria added, which allows a higher quantity limit for T1DM patients during pregnancy.
Lialda (mesalamine)	Add to formulary with equivalent status to Asacol, Delzicol, and Pentasa.
Cholecalciferol (vitamin D3) drops	Add to formulary (400 units/mL strength)
Crestor (rosuvastatin)	Add to formulary (remove PA requirements)
Pravachol (pravastatin)	Add to formulary (remove PA requirements)
Prometrium (micronized progesterone)	Add to formulary (remove PA requirements). Quantity limit #30/month.
Vivelle Dot (estradiol) patch	Add to formulary (remove PA requirements). Quantity limit #8/month.
Voltaren (diclofenac) 1% gel	Add to formulary (remove PA requirements). Quantity limit 100gm/month.
Seasonale (levonorgestrel/ethinyl estradiol)	Add to formulary (remove PA requirements).
Ella (ulipristal)	Remove quantity limits.
Aldactazide (spironolactone/HCTZ) 50/50mg (brand)	Remove from formulary. Zero utilization, brand agent (generics available).
Neptazane (methazolamide)	Remove from formulary. Zero utilization, therapeutic alternate(s) available on formulary.
Zenpep (lipase/protease/amylase) 40K-136K	Add to formulary.
Repatha (evolocumab)	Add to formulary with prior authorization.

New Product Reviews

- | | |
|---------------------------------|-----------------|
| • Linzess | • Kisqali |
| • Selzentry | • Siliq |
| • Triferic | • Ixinity |
| • Trulance | • Lartruvo |
| • Dilaudid | • Synjardy XR |
| • Adynovate | • Ocrevus |
| • Emflaza | • Dupixent |
| • Daxbia | • Bavencio |
| • Ryvent | • Gammaplex 10% |
| • Xermelo | • Austedo |
| • Zonacort | • Gelnique |
| • Arymo ER | • Airduo |
| • Vyvanse | • Kovanaze |
| • Rhofade | • Esbriet |
| • Eloctate | • Ingrezza |
| • Ilaris | • Tepadina |
| • Nipride RTU | • Zejula |
| • Bevacizumab | • Quflora FE |
| • Cyclopentolate-Lido-PE-Tropic | • Tymlos |
| • Zytiga | • Lidopac |
| • Herceptin | • Rydapt |
| • Kisqali Femara Co-Pack | • Alunbrig |
| • Morphabond ER | • Imfinzi |
| • Keramatrix | • Narcan |
| • Gelfoam JMI | • Adynovate |
| • Tranzarel | • P-Care |
| • Orencia | • Iohexol |
| • Brineura | • Radicava |
| • Kevzara | • Xatmep |
| • Xadago | • Rubraca |